Recombinant interferon alpha-2 (INTRON A) in a phase II study of XXXX .

@entity1 @entity137 @entity1910 @entity1295 @entity1358 @entity74 @entity3 @entity221
Because two of five @entity1 with @entity1358 in a Phase I study had partial response to recombinant alpha-2 interferon (IFN), we treated 26 @entity1 with @entity1358 with a 3-month regimen of IFN. @entity1 were randomized to receive IFN either subcutaneously (2 X 10(6) IU/m2 3 times a week) or intravenously (3 X 10(7) IU/m2 for 5 consecutive days every 2-3 weeks). @entity1 whose disease was responding or stable were treated further, while those with @entity74 on subcutaneous treatment were offered intravenous therapy. Sites of @entity3 included lung (14 @entity1 ), bone (7 @entity1 ), soft tissue (7 @entity1 ) and liver (2 @entity1 ). Twenty @entity1 were evaluable for response. One @entity1 had a partial response at the end of the third course of intravenous IFN and subsequently had complete disappearance of a 12 X 7 cm subcutaneous mass after the seventh course of treatment. The disease was stable in 13 @entity1 including two minor responses, and six @entity1 had @entity74 (5 with subcutaneous treatment; 1 with intravenous treatment) including one mixed response. All @entity1 experienced early flu-like symptoms of @entity221 , chills, and rigors during the first few days of treatment and most had mild to moderate @entity1295 . Three @entity1 left the study because of @entity1295 , and one had an @entity1910 . From these results and our previous experience, it appears that IFN has activity against @entity1358 with acceptable @entity137 .
